- Table View
- List View
PFIN
by Randall Billingsley Lawrence J. Gitman Michael D. Joehnk4LTR Press solutions give students the option to choose the format that best suits their learning preferences. This option is perfect for those students who focus on the textbook as their main course resource.
PFIN5: Personal Finance
by Randall S. Billingsley Lawrence J. Gitman Michael D. JoehnkNIMAC-sourced textbook
Pfizer: Letter from the Chairman (A)
by Natalie Kindred Robert L. SimonsThis case explores maximizing shareholder value as a goal in executive decision making. Over a period of nine years, three different Pfizer CEOs make critical decisions intended to increase shareholder value. But the results are disappointing. To allow students to examine these decisions, the case provides excerpts from four Chairman's letters to shareholders from Pfizer's annual reports, followed by a description of the circumstances behind each letter. In the 2000 annual report, then-CEO Bill Steere discusses Pfizer's rise to industry prominence with the acquisition of Warner-Lambert. In the 2003 report, new CEO Hank McKinnell discusses Pfizer's performance goals and its acquisition of Pharmacia, which gave it control of anti-arthritis drug Celebrex. In the 2005 report, McKinnell discusses his decision to keep Celebrex on the market despite health risks. In the 2006 report, new CEO Jeff Kindler barely mentions McKinnell's (controversial) early retirement and describes efforts to reform the company. The case closes in February 2009, just after Pfizer announces plans to acquire competitor Wyeth. Since 2000, Pfizer's tremendous growth in assets through acquisitions has not translated into significant growth in net income or share price. In closing, students are asked what Kindler should write in the letter to shareholders to open Pfizer's 2008 annual report.
Pfizer: Global Protection of Intellectual Property
by Lynn Sharp Paine Michael A. SantoroTop officials at Pfizer are assessing their strategy for improving protection of Pfizer's patents around the world. The outcome of the Uruguay Round of the GATT negotiations is uncertain, and it is not clear whether an acceptable intellectual property protection agreement will emerge. The case describes how Pfizer helped transform intellectual property from a lawyer's specialty to an international trade issue of concern around the world through close cooperation with the U.S. government, leadership in forming a tripartite coalition among U.S., Japanese, and European industry, and mobilization of the Pfizer organization. Shows how far a company may go to protect its intellectual property in a world where the concept of intellectual property is not universally recognized or accepted. May also be used to discuss the effectiveness and legitimacy of Pfizer's strategy, the conflicts between industrialized country and developing country perspectives on international trade and national sovereignty, and the question of appropriate norms of intellectual property protection.
Pfizer and AstraZeneca: Marketing an Acquisition (A)
by John A. Quelch James WeberIn 2014, Pfizer proposed a friendly acquisition of AstraZeneca, but the AstraZeneca board resisted over price and strategy concerns. Was this good for pharmaceutical consumers? Pfizer, like pharmaceutical companies in general, faced difficulties in growing sales due to the challenges of developing new drugs. Over the previous decade or more, Pfizer had pursued acquisitions as a way to acquire new drugs, increase sales, and to reduce costs by combining operations and cutting staff. Pfizer, a U.S. company, was also interested in AstraZeneca, a U.K. company, as a way to reduce its corporate taxes. In recent years, AstraZeneca had significantly strengthened its pipeline of potential new drugs and its board felt it was in a strong position to go it alone. The company's CEO also indicated that an acquisition would be disruptive to its drug development efforts and delay new drugs coming to market. U.K. politicians expressed concerns over downsizing and job losses in the economically important pharmaceutical sector. The case allows readers to explore who benefits from a potential acquisition (shareholders, employees, drug consumers) and which of these stakeholders should be considered when deciding on an acquisition.
Pfizer and AstraZeneca: Marketing an Acquisition (B)
by John A. Quelch James WeberThis (B) case provides a brief description of the outcome of the (A) case.
Pfizer: Global Protection of Intellectual Property
by Lynn Sharp Paine Michael A. SantoroTop officials at Pfizer are assessing their strategy for improving protection of Pfizer's patents around the world. The outcome of the Uruguay Round of the GATT negotiations is uncertain, and it is not clear whether an acceptable intellectual property protection agreement will emerge. The case describes how Pfizer helped transform intellectual property from a lawyer's specialty to an international trade issue of concern around the world through close cooperation with the U.S. government, leadership in forming a tripartite coalition among U.S., Japanese, and European industry, and mobilization of the Pfizer organization. Shows how far a company may go to protect its intellectual property in a world where the concept of intellectual property is not universally recognized or accepted. May also be used to discuss the effectiveness and legitimacy of Pfizer's strategy, the conflicts between industrialized country and developing country perspectives on international trade and national sovereignty, and the question of appropriate norms of intellectual property protection.
Pfizer Inc.: Building an Innovation Center
by Ashok Nimgade Stefan ThomkeThe case describes Pfizer's efforts to build and run an innovation center in Cambridge, Massachusetts. As the center goes through different periods of leadership and strategic models, its relationship with the corporation and other research sites is explored. The case study describes in detail the challenges of building an innovation center within a large corporation, including organization, incentives, and scientific issues.
Pfizer's Centers for Therapeutic Innovation (CTI)
by Gary P. Pisano Kaitlyn Szydlowski James WeberIn 2010, Pfizer established four small research units in New York, Boston, San Francisco, and San Diego located close to several premier Academic Medical Centers (AMCs), or hospitals with adjoining medical schools. The goal of these units was to redesign collaboration with Pfizer and academic medical researchers with the purpose of developing new, innovative drugs candidates for testing in patients. Project teams consisted of Pfizer scientists and academics working side-by-side to reduce the time needed to bring a therapeutic drug from the lab to a patient's bedside. This case explores the academic collaboration model developed by Pfizer. What were the strengths of and challenges facing this model? How would the model evolve in the future? And how would new, similar collaboration models surfacing at other major pharmaceutical companies pose a threat to the Pfizer model?
Pfizer's Virtual CIO (Abridged)
by F. Warren Mcfarlan Brian J. DelaceyDiscusses the IT organization and IT strategy issues facing Pfizer, one of the world's largest pharmaceutical companies. Managing over $1 billion of IT expense, the company has a committee approach for handling all critical IT decisions, an approach that is consistent with the internal culture of Pfizer in other aspects.
Pflege im Wandel gestalten – Eine Führungsaufgabe: Lösungsansätze, Strategien, Chancen
by Kathrin Lipp Ingrid Smerdka-Arhelger Peter BechtelDas Buch ist ein Führungskompass für Leitende in Gesundheitseinrichtungen, die ihr Team aktiv in Veränderungsprozessen begleiten möchten. Namhafte Experten beschreiben die Herausforderungen, die auf Einrichtungen der Kranken- und Altenpflege zukommen, erläutern Lösungsansätze und wagen einen Ausblick in die Zukunft. Ziel ist es, die Einrichtungen zukunftssicher zu machen, und den Leitungskräften Handwerkszeug zu liefern, mit den neuen Herausforderungen umzugehen. Dabei bilden die 3 wichtigsten Veränderungsfaktoren Prozesssteuerung, Fachpersonal und Demografie den roten Faden des Buches.Erläutert werden Fragen wie: Mitarbeiter 50+ - Wie nutze und fördere ich das Potenzial dieser Ressource?, Mitarbeiterzufriedenheit - Wie binde ich Mitarbeiter an meine Einrichtung?, Nachwuchsmangel – Wie wird meine Einrichtung zum Magnet?, Lebenslanges Lernen – Fachliche Kompetenz schulen und eine positive Haltung im Berufsfeld Pflege entwickeln, Zu gesund für‘s Krankenhaus, zu krank für zu Hause – Wie können Versorgungsstrukturen verbessert werden? Best Practice-Konzepte von Kliniken und Pflegeeinrichtungen sowie ein Blick in andere europäische Länder geben Beispiele, wie der Wandel positiv für neue Ansätze genutzt wird.Für Krankenhausmanager, Pflegedirektoren, Pflegedienst- und Stationsleitungen, Qualitätsmanager in Krankenhäusern und Altenpflegeeinrichtungen, die ihr Team sicher in die Zukunft navigieren möchten.
Pflegeeinrichtungen erfolgreich führen: Organisationskultur zwischen Marktorientierung und Berufsethik
by Heinrich BolzDas Buch stellt den Erfolgsfaktor der marktorientierten Organisationskultur für Pflegeeinrichtung in den Mittelpunkt der Betrachtung. Die wesentlichen inhaltlichen und methodischen Grundlagen zur Organisationskultur und zum Changemanagement werden verständlich aufbereitet. Die Bearbeitung des Themas verknüpft wissenschaftlich fundierte Grundlagen und Erkenntnisse zur Organisationskultur mit praxisnahen Bezügen und Beispielen aus dem Pflegealltag. Es wird konkrete Hilfestellung für eine Selbstreflexion und Erfassung der bestehenden Organisationskultur gegeben.
Pflegeinnovationen in der Praxis: Erfahrungen und Empfehlungen aus dem „Cluster Zukunft der Pflege“
by Tobias Krick Jürgen Zerth Heinz Rothgang Ronny Klawunn Stefan Walzer Tobias KleyPflegeinnovationen - insbesondere in Verbindung mit Digitalisierung und den Potenzialen von KI - werden als wesentlicher Hebel gesehen, um sowohl die Qualität in der Pflege anzuheben als auch den wachsenden Herausforderungen des Fachkräftemangels zu begegnen. Die Frage, welche Faktoren die Entwicklung, Auswahl und Implementierung von Pflegetechnologien befördern oder auch behindern können, ist die Aufgabe des vom Bundesministerium für Bildung und Forschung (BMBF) geförderten „Cluster Zukunft der Pflege“. Dabei wird das gesamte soziotechnische System Pflege (Mensch, Organisation und Technik), in dem die Technik zum Einsatz kommen soll, betrachtet.An Beispielen aus dem Pflegeinnovationszentrum (PIZ) und aus vier Pflegepraxiszentren (PPZ) werden in diesem Buch die Phasen des Technologieentwicklungsprozesses und der Implementierung von Pflegeinnovationen in diversen pflegerischen Settings des praktischen Pflegealltags vorgestellt, die Fragen nach sozialer, ethischer und ökonomischer Relevanz sowie die Bedeutung des praktischen Nutzens sowie der Akzeptanz gestellt und diskutiert. Zugleich werden Bedingungsfaktoren für gelingende Pflegeinnovationen analysiert, damit sich der pflegerische Nutzen der Pflegebedürftigen und der Nutzen der Pflegenden verbessern lassen. Kurz: Ein profunder Einblick in die Werkstatt „Zukunft der Pflege“ mit zahlreichen praxisorientieren Erkenntnissen für den Einsatz von digitalen Innovationen im Pflegealltag und Hinweisen für den weiteren Entwicklungs- und Forschungsbedarf.
Pflegemanagement und Innovation in der Pflege: Wie sich Mensch und Maschine sinnvoll ergänzen (FOM-Edition)
by Gerald Lux David MatusiewiczDie Pflegebranche in Deutschland ist im Umbruch – sie muss dem zunehmenden Fachkräftemangel etwas entgegensetzen und zugleich als eine der Zukunftsbranchen die Potenziale der Technisierung und Digitalisierung heben.Dieses Buch erfasst und analysiert die derzeitigen Trends und Herausforderungen sowohl im Bereich der praktischen Pflege als auch auf der Ebene des Pflegemanagements auf allen Führungsebenen. Die Autoren der 30 wissenschaftlichen Beiträge zeigen, wie politische Entscheider, die Organe der Selbstverwaltung und die einzelnen Unternehmen durch unterschiedliche Maßnahmen den Problemen der Pflegebranche entgegenwirken können. Es werden eine Reihe von Handlungsmöglichkeiten und Entwicklungsperspektiven für die unterschiedlichen Akteure der Pflegebranche aufgezeigt, bei denen sich der Faktor Mensch und der Faktor Maschine sinnvoll ergänzen können. Auch werden Pflegekonzepte mit in den Blick genommen, die bisher weniger bekannt sind. Ebenso werden innovative Ansätze von Start-ups und sozialen Entrepreneuren in der Pflege präsentiert.Nicht zuletzt die Corona-Pandemie hat gezeigt, dass die Pflege eine zentrale, systemrelevante Stütze im Gesundheitswesen in Deutschland darstellt. Die jüngsten Reformen in der Pflegepolitik sind Ausdruck davon und zeigen, dass sich Entscheider auf allen Ebenen und in allen Bereichen der Pflege mit den drängenden Fragen auseinandersetzen müssen. Dazu liefert dieses Buch wichtige Impulse und Anregungen.
Pflegeroboter
by Oliver BendelDieses Open-Access-Buch bündelt technische, wirtschaftliche, medizinische und ethische Reflexionen über Pflegeroboter. Pflegeroboter, im Moment noch mehrheitlich Prototypen, unterstützen oder ersetzen menschliche Pflegekräfte bzw. Betreuer. Sie bringen Kranken und Alten die benötigten Medikamente und Nahrungsmittel, helfen beim Hinlegen und Aufrichten oder alarmieren den Notdienst. Vorteile von Pflegerobotern sind durchgehende Verwendbarkeit und gleichbleibende Qualität der Dienstleistung. Nachteile sind Kostenintensität (bei möglicher Amortisation) und Komplexität der Anforderungen. Unter der wissenschaftlichen Leitung von Prof. Dr. Oliver Bendel trafen sich im September 2017 Vertreter verschiedener wissenschaftlicher Disziplinen im Rahmen eines Ladenburger Diskurses der Daimler und Benz Stiftung, um über den aktuellen und künftigen Einsatz von Pflegerobotern zu sprechen und Forschungspotenziale zu identifizieren. Die Autoren gehen in ihren Beiträgen auch Fragen aus Wirtschafts-, Medizin- und Informationsethik nach: Wer trägt die Verantwortung bei einer fehlerhaften Betreuung und Versorgung durch die Maschine? Inwieweit kann diese die persönliche und informationelle Autonomie des Patienten unterstützen oder gefährden? Ist der Roboter eine Entlastung oder ein Konkurrent für Pflegekräfte? Antworten müssen von Wissenschaft und Gesellschaft gefunden werden.
PfMP Exam Practice Tests and Study Guide (Best Practices in Portfolio, Program, and Project Management)
by PMP, PgMP, LevinRecognizing the importance of portfolio management, the Project Management Institute (PMI) has launched a new certification entitled the Portfolio Management Professional (PfMP). PfMP Exam Practice Tests and Study Guide is the most comprehensive resource available to help you prepare for and pass the PfMP certification exam. It provides covera
PFA Pension: Expansion of Alternatives Portfolio
by Federica Gabrieli Jerome Lenhardt Victoria IvashinaPFA Pension was the biggest commercial pension provider in Denmark. At the end of 2015, the company had decided to boost its investments into the alternative asset class, an area where it was lagging behind its competitors. The aim was to privilege direct investments and co-investments rather than allocations through funds. One year later, PFA could count on an expert alternative investment team, a defined investment process and a number of successful direct investments. Still, a number of questions remained: How could PFA better access attractive deal opportunities? Should PFA try to build a formal deal sourcing model? What resources and skills would be necessary to add to the alternative investment team?
PFA Pension: Expansion of Alternatives Portfolio
by Federica Gabrieli Jerome Lenhardt Victoria IvashinaPFA Pension was the biggest commercial pension provider in Denmark. At the end of 2015, the company had decided to boost its investments into the alternative asset class, an area where it was lagging behind its competitors. The aim was to privilege direct investments and co-investments rather than allocations through funds. One year later, PFA could count on an expert alternative investment team, a defined investment process and a number of successful direct investments. Still, a number of questions remained: How could PFA better access attractive deal opportunities? Should PFA try to build a formal deal sourcing model? What resources and skills would be necessary to add to the alternative investment team?
PFA Pensions: The Climate Plus Product
by Alys Ferragamo Daniel Green Victoria IvashinaThe case explores whether alternative investments play a unique role in achieving low carbon dioxide emissions at the portfolio level. This case is set in April of 2020 and follows Kasper Ahrndt Lorenzen, Chief Investment Officer, and Peter Tind Larsen, Head of Alternative Investments, at PFA, the largest commercial pension fund in Denmark. PFA had recently seen increased demand from its corporate clients to offer a product with lower carbon dioxide emissions. The case explores PFA's decision to offer a "Climate Plus" product that would aim to produce strong returns and meet ambitious climate-related goals. In the case, the protagonists meet to discuss the role of alternative assets in the product. Importantly, PFA already has a significant presence in the alternative space and, in particular, in private equity and renewable energy. A large fraction of their alternative portfolio is managed in-house. Among other things, PFA is thinking about adding timberland investments as a new asset class to achieve net zero emissions. Lorenzen and Larsen need to determine if they could leverage their existing team and processes to invest in timberland and whether it is the right time to launch a climate-focused product. This case provides a good platform for discussion on direct investing in the alternative space and the role of alternatives for large institutional investors.
PG&E and the First Climate Change Bankruptcy
by Stuart C. Gilson Sarah L. AbbottIn early 2020, the California-based utility PG&E filed a second amended plan of reorganization. PG&E had filed for Chapter 11 bankruptcy in the face of more than $30 billion of legal claims brought against it for its alleged role in causing California wildfires. The plan had the support of key creditors and shareholders and a court-appointed committee representing the wildfire victims. However, it faced strong opposition from California's governor, Gavin Newsom, who was concerned that PG&E's plan would leave it too highly leveraged, and unable to make necessary investments. Were Newsom's concerns valid ones? Did the plan as currently envisioned leave the reorganized PG&E with too much debt to meet its obligations to the wildfire victims while still making the necessary investments to update its equipment? And was PG&E prepared for the new reality of climate change?
PgMP Exam Challenge! (ESI International Project Management Series #17)
by Ginger Levin PMP PgMP J. LeRoy Ward PMP PgMPUp to date with the third edition of PMI's Program Management Standard, The PgMP Exam Challenge! contains more than 300 practice questions to help readers hone their knowledge and test their skills. It covers all five of the program management domains: Strategic Program Management, Program Management Life Cycle, Benefits Management, Stakeholder Management, and Governance. It also examines all of the sub domains of the lifecycle domain. With an easy-to-use format, this is an ideal resource for those preparing to take the PgMP exam.
PgMP Exam Practice Test and Study Guide (ESI International Project Management Series)
by Ginger Levin J. LeRoy WardUp to date with the third edition of PMI's Standard for Program Management, this is the most comprehensive resource available to help prepare readers for the PgMP Exam. Updated with new and changed terminology, this edition incorporates the concepts from the five performance domains. The book features practical study hints, a list of major topics covered on the exam, and a bibliographic reference for further study. The two challenging, 170-question practice tests are available in the book and online so readers can retake the practice tests as many times necessary.
PgMP® Exam Test Preparation: Test Questions, Practice Tests, and Simulated Exams (Best Practices in Portfolio, Program, and Project Management)
by Pmp Ginger Levin PgMPIn addition to test questions in each of the five domains and two practice tests in print and online, this all-in-one study guide also contains flashcards for learning terms. This book is current with The Standard for Program Management, Fourth Edition, and its author is the second person in the world to have earned the PgMP® certification. The online versions of the practice test simulate taking the actual exams and provide scoring as above target, target, below target, or needs improvement. Answers come with explanations and references. Questions are written to improve reading skills and teach how to select the best answer, which are key to passing the exam.
PgMP Practice Test Questions: 1000+ Practice Exam Questions for the PgMP Examination
by Ginger LevinUp to date with the fourth edition of PMI’s Program Management Standard, PgMP® Practice Test Questions: 1000+ Practice Exam Questions for the PgMP® Examination contains more than 1,000 practice questions to help readers hone their knowledge and test their skills. It covers all five of the program management domains: Strategic Program Management, Program Management Life Cycle, Benefits Management, Stakeholder Management, and Governance. It also examines all of the sub domains of the lifecycle domain. With an easy-to-use format, this is an ideal resource for those preparing to take the PgMP® exam.
The Phantom Capitalists: The Organization and Control of Long-Firm Fraud
by Michael LeviThis book analyzes in detail how and why people become involved in long-firm (planned bankruptcy) fraud, the similarities and differences between long-firm fraud and other crimes, the links between bankruptcy fraudsters and other professional and organized criminals, the techniques that fraudsters use, and the social and commercial relationships that exist within the operational world of the long-firm fraudster. Extensively researched, the study uses interviews with and documentation from businesspeople, credit controllers, lawyers, judges, police, fraud investigators as well as fraudsters themselves. It also makes use of extensive documentary material from contemporary and historical police and court records. Originally published in the 1980s, the revised edition of this seminal work provides a substantial new introduction written by the author to highlight the changing and unchanging relevance of the findings for a contemporary audience, and the ways in which fraud opportunities and the organization of frauds have modified in the intervening years.